Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


sarah.pearson@oncology.ox.ac.uk


01865 227160
01865 227177


octo-enquiries@oncology.ox.ac.uk


https://www.oncology.ox.ac.uk/research/srf/oncology-clinical-trials-office-octo


ORCID ID https://orcid.org/0000-0001-5386-1953


OCTO, Department of Oncology, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, United Kingdom, OX3 7DQ

Sarah Pearson

BSc

OCTO Trial Management Director

OCTO Trial Management Director

After a degree in Human Biology I worked on Cancer Research Campaign epidemiology projects in Oxford looking at leukaemia, and assessing incidence of cancer in immunosuppressed renal transplant patients. I subsequently moved to work on ICRFs funded projects based in an NHS clinical genetics department supporting recruitment and data collection for projects on screening intervals for patients with family histories of cancer and the psychological impact of familial cancers.   Driven by an interest to work in research with a more direct impact on cancer patient care, I joined the OCTO as a Clinical Trial Coordinator in 2004, became a project manager in 2007 and the group’s Trial Management Director in 2008.    The role involves leading the operational activity in the CTU including the specialist teams which design and deliver a broad portfolio of CTIMPs, non-CTIMPs and device trials.

I led the OCTO team through a merger with other Oxford CTUs which created the UKCRC Registered CTU OCTRU, and have adapted the operational structures from supporting late phase trials to specialising in delivery of early phase (FIH to phase II) trials.